Literature DB >> 18198369

Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping.

Garth M Funston1, Susanna E Kallioinen1, Pablo de Felipe1, Martin D Ryan2, Richard D Iggo1.   

Abstract

Insertion of picornaviral 2A sequences into mRNAs causes ribosomes to skip formation of a peptide bond at the junction of the 2A and downstream sequences, leading to the production of two proteins from a single open reading frame. Adenoviral protein IX is a minor capsid protein that has been used to display foreign peptides on the surface of the capsid. We have used 2A sequences from the foot-and-mouth disease virus (FMDV) and porcine teschovirus 1 (PTV-1) to express protein IX (pIX) and green fluorescent protein (GFP) from pIX-2A-GFP fusion genes in an oncolytic virus derived from human adenovirus 5. GFP was efficiently expressed by constructs containing either 2A sequence. Peptide bond skipping was more efficient with the 58 aa FMDV sequence than with the 22 aa PTV-1 2A sequence, but the virus with the FMDV 2A sequence showed a reduction in plaque size, cytopathic effect, viral burst size and capsid stability. We conclude that ribosome skipping induced by 2A sequences is an effective strategy to express heterologous genes in adenoviruses; however, careful selection or optimization of the 2A sequence may be required if protein IX is used as the fusion partner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18198369     DOI: 10.1099/vir.0.83444-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

1.  Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Authors:  Jan Ole Kemnade; Mamatha Seethammagari; Priya Narayanan; Jonathan M Levitt; Alison A McCormick; David M Spencer
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

2.  Acquiring transgenic tobacco plants with insect resistance and glyphosate tolerance by fusion gene transformation.

Authors:  He Sun; Zhihong Lang; Li Zhu; Dafang Huang
Journal:  Plant Cell Rep       Date:  2012-07-10       Impact factor: 4.570

3.  Versatile co-expression of graft-protective proteins using 2A-linked cassettes.

Authors:  Nella Fisicaro; Sarah L Londrigan; Jamie L Brady; Evelyn Salvaris; Mark B Nottle; Philip J O'Connell; Simon C Robson; Anthony J F d'Apice; Andrew M Lew; Peter J Cowan
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

4.  PAX4 Gene Transfer Induces α-to-β Cell Phenotypic Conversion and Confers Therapeutic Benefits for Diabetes Treatment.

Authors:  Yanqing Zhang; Genevieve E Fava; Hongjun Wang; Franck Mauvais-Jarvis; Vivian A Fonseca; Hongju Wu
Journal:  Mol Ther       Date:  2015-10-05       Impact factor: 11.454

5.  Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy.

Authors:  Christina Quirin; Stanimira Rohmer; Inés Fernández-Ulibarri; Michael Behr; Andrea Hesse; Sarah Engelhardt; Philippe Erbs; Alexander H Enk; Dirk M Nettelbeck
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

Review 6.  The evolutionary consequences of erroneous protein synthesis.

Authors:  D Allan Drummond; Claus O Wilke
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

Review 7.  Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.

Authors:  Joshua Del Papa; Ryan G Clarkin; Robin J Parks
Journal:  Cancer Gene Ther       Date:  2020-07-01       Impact factor: 5.987

8.  Tagging of genomic STAT3 and STAT1 with fluorescent proteins and insertion of a luciferase reporter in the cyclin D1 gene provides a modified A549 cell line to screen for selective STAT3 inhibitors.

Authors:  Andrey Samsonov; Nathan Zenser; Fan Zhang; Hongyi Zhang; John Fetter; Dmitry Malkov
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  Comparison of IRES and F2A-based locus-specific multicistronic expression in stable mouse lines.

Authors:  Hsiao Yun Chan; Sivakamasundari V; Xing Xing; Petra Kraus; Sook Peng Yap; Patricia Ng; Siew Lan Lim; Thomas Lufkin
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

10.  Theranostic potential of oncolytic vaccinia virus.

Authors:  Juan J Rojas; Steve H Thorne
Journal:  Theranostics       Date:  2012-04-05       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.